- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07950306
Kidney Blood Flow During Open Aortic Surgery (RENAL-SHUNT) (RENAL-SHUNT)
Prospective Observational Evaluation of Temporary Selective Renal Blood Perfusion During Open Aortic Surgery With Suprarenal Cross-Clamping
During some operations on the abdominal aorta, the surgeon needs to temporarily clamp the aorta above the arteries that supply the kidneys. This can reduce blood flow to the kidneys and may cause acute kidney injury.
This study will follow 50 adults at Policlinico di Sant'Orsola in Bologna, Italy. During their operation, a temporary shunt will perfuse blood from humeral artery to the renal arteries. The treating surgeon decides whether to use the shunt as part of clinical care, independently of study participation.
The researchers will record how often kidney injury occurs in the first 7 days after surgery and how often problems related to the shunt, kidney arteries or arm access occur within 30 days. They will also track the need for dialysis, kidney function and survival over 12 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RENAL-SHUNT is a single-center prospective observational registry of adults undergoing open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping. The surgical team may select passive renal blood perfusion when it anticipates prolonged or uncertain renal ischemia or considers the patient at high renal risk. The study observes a single exposed cohort. Treatment decisions are made independently of enrollment.
The registry will record baseline kidney function and preoperative acute kidney injury, aortic pathology, urgency, clamp level, periods of renal ischemia and perfusion, hemodynamics, transfusion and complications. Serum creatinine will be collected from routine postoperative assessments where available. Recorded urine output will be used for Kidney Disease: Improving Global Outcomes (KDIGO) classification when available. Follow-up assessments include discharge and postoperative days 30 and 90 and months 6 and 12.
The study targets 50 consecutive participants based on expected accrual over up to 5 years. Event rates will be presented as counts and percentages with 95% confidence intervals. At an observed rate of 20% (10 of 50), the Wilson 95% confidence interval would be approximately 11% to 33%. Changes in serum creatinine and estimated glomerular filtration rate will be summarized from baseline. Subgroup and longitudinal analyses will be exploratory.
The investigators will maintain a screening log and collect data in a coded electronic case report form with a data dictionary and prespecified time windows. Range, consistency and missing-data checks will be completed before database lock. Two investigators will review acute kidney injury stage, major adverse kidney events and serious technique-related events when feasible. Available denominators will be reported for each outcome. The primary outcome will use observed data, with a creatinine-only analysis when urine-output records are incomplete.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Rodolfo Pini, MD, PhD, FEBVS
- Phone Number: +39-0512143288
- Email: rodolfo.pini2@unibo.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults undergoing open abdominal aortic reconstruction with suprarenal or supravisceral cross-clamping at Policlinico di Sant'Orsola in Bologna, Italy, for whom the surgical team selects temporary renal blood perfusion.
Description
Inclusion Criteria:
-
Age 18 years or older.
-
Open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping.
-
Independent clinical decision by the treating surgeon to use the described renal perfusion circuit.
-
At least one renal artery intended for shunt perfusion.
-
Written informed consent before surgery through the approved process.
Exclusion Criteria:
-
Maintenance kidney replacement therapy before surgery.
-
No initiation of renal shunt perfusion after consent.
-
Inability or unwillingness to provide informed consent under the approved process.
-
Pregnancy.
-
Primary renal perfusion using cardiopulmonary bypass or a dedicated visceral perfusion system.
-
Clinical contraindication to brachial access or renal ostial cannulation.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative acute kidney injury
Time Frame: End of surgery through postoperative day 7
|
Number and percentage of participants meeting KDIGO 2012 criteria. Acute kidney injury is defined by a serum creatinine rise of at least 0.3 mg/dL within 48 hours, serum creatinine at least 1.5 times the reference within 7 days, or urine output below 0.5 mL/kg/hour for at least 6 hours. Reference creatinine is the most recent stable value 7 to 90 days before surgery, or the preoperative value if a stable historical value is unavailable. Cases with preoperative acute kidney injury will be adjudicated and described separately. |
End of surgery through postoperative day 7
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RENAL-SHUNT-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.